Old drug, new hope: ATRA combo targets tough pancreatic cancer
NCT ID NCT04241276
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase IIb trial tests whether adding ATRA (a vitamin A derivative) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with locally advanced pancreatic cancer live longer without their cancer growing. About 170 participants will receive either the combo or standard chemo. The main goal is to see if the new mix delays tumor progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ATRA (tretinoin) plus gemcitabine and nab-paclitaxel
What this could lead to
If successful, this could offer a new treatment option that slows the growth of locally advanced pancreatic cancer.
What could go wrong
This is a mid-stage trial with 170 people, so results are not yet proven. The drug combination may not work better than standard chemo and could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barts NHS Trust
London, United Kingdom